All News

The A-NEW study found that 42% of breast cancer survivors with slower early weight loss reached the 5% goal after Contrave was added.

FDA approves BESREMi for adults with essential thrombocythemia, offering a new treatment option for people living with this rare blood cancer.

FDA approves Mimrylo (rusfertide) for adults with polycythemia vera, offering a new treatment approach that may reduce the need for frequent blood draws.

After breast cancer treatment ends, survivorship can bring unexpected challenges. One survivor shares how she learned to heal and redefine who she is.

A stage IV kidney cancer survivor shares how 10 years of treatment changed his view of success, uncertainty, fear and finding meaning in everyday life.

Ivonescimab plus chemotherapy improved survival compared with Imfinzi plus chemotherapy in patients with previously untreated advanced biliary tract cancer, according to phase 3 findings.

A breast cancer survivor reflects on managing lymphedema, navigating Dupuytren’s disease and finding perspective when new health challenges arise.

Theresa Gannon’s compassion, leadership and dedication to patients and fellow oncology nurses make her an Extraordinary Healer Award nominee.

Dr. Maria Margarete Karsten discusses how weekly symptom monitoring helped identify changes between visits and what patients told her about using it.

Jim Day was told he had six months to live after a stage 4 melanoma diagnosis. A cancer-fighting virus helped shrink his tumors and gave him hope.

Health insurance is changing. The coming months will bring some of the most significant updates to Medicaid and Marketplace coverage in decades.

A UCLA study found patients with cancer who used biosimilars paid less out of pocket, and their insurers paid far less, than those on brand-name biologics.

Researchers are studying how genetics and environmental factors may influence lung cancer risk and could help shape the future of screening and treatment.

In the phase 2/3 STAR-TREC trial, 78.5% of patients given long-course chemoradiotherapy kept their rectum at 12 months, versus 60.6% with short-course radiotherapy.

In the phase 3 SHARE trial, salvage radiation given in 26 sessions kept cancer in check as well as 33 sessions did, with more late bowel side effects.

Rasonque offers a new targeted treatment option for metastatic pancreatic cancer. Dr. Kristin Higgins explains the approval, trial results and side effects.

I have worked alongside Lori Ranallo for 23 years and watched her guide patients with breast cancer from diagnosis through survivorship and beyond.

GYN oncologist Dr. Ami Vaidya, explains what gynecologic cancers are, why awareness matters and how patients can learn to recognize symptoms.

Nona Baker discusses the misdiagnoses that came first, why families need support and what has changed since.

A friend’s 28-year cancer journey taught one woman how to find hope, stay optimistic and live fully after her own incurable cancer diagnosis.

FDA approves Rasonque, a first-in-class targeted therapy for metastatic pancreatic cancer, offering a new treatment option for eligible patients.

A testicular cancer survivor shares his story of early detection, embracing failure, and redefining success through hard-won life lessons.

Dolly Parton has died at 80 following a brief battle with cancer. Learn what is known about her diagnosis, legacy and resources for those affected.

In a new video Q&A with CURE, Dr. Silverman answers the most searched childhood leukemia questions.

An incoming medical oncologist at the University of Cincinnati on how patient values shape treatment, and what precision medicine can now target.

Breast oncologist Dr. Zunairah Shah explains how breast cancer research is improving treatment, biomarker testing and options such as antibody-drug conjugates.

FDA approves Ziihera combinations for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma, expanding treatment options.

Dr. Matthew Karr explains how CAR T-cell therapy works, who may be eligible and how doctors decide when to treat or monitor cancer.